2026 Volume: 02 Issue: 06 www.ijrpa.com ISSN 2456-9995 Research Article

International Journal Research Publication Analysis

Page: 01-06

FUTURE DIRECTIONS AND RESEARCH GAPS IN STEM-CELL THERAPY FOR TYPE 1 DIABETES

Geetanjali Amat*, Adyasha Majhi, Bhabani Shankar Mahapatra, Surya Narayan Das

Gayatri college of pharmacy, Gayatri Bihar, Jamadar Pali, Sambalpur,768200.

Article Received: 03 June 2026
Article Revised: 23 June 2026
Published on: 13 July 2026

***Corresponding Author: Geetanjali Amat**
Gayatri college of pharmacy, Gayatri Bihar, Jamadar Pali, Sambalpur,768200.

DOI: https://doi-doi.org/101555/ijrpa.3158

ABSTRACT

Stem cell–based therapies are increasingly recognized as promising disease-modifying strategies for T1D, with the goal of restoring endogenous insulin secretion or reestablishing immune regulation. Significant scientific and translational limitations still plague the area, despite early clinical trials and case reports suggesting partial or total insulin independence in certain individuals. The main unresolved research gaps in the field of stem-cell therapy for type 1 diabetes are summarized in this review. These gaps include the lack of long-term randomized trials, a lack of knowledge about autoimmune relapse, difficulties with immune protection, safety concerns, scalability issues, and disjointed regulatory frameworks. Addressing these voids is essential for the progression of stem-cell therapies from experimental procedures to clinically effective and globally accessible treatments.

INTRODUCTION

A lifelong need on exogenous insulin is the outcome of type 1 diabetes mellitus, a chronic autoimmune illness marked by immune-mediated death of pancreatic β cells. Current treatments do not address the underlying autoimmune pathology or restore endogenous insulin production, despite advancements in glucose monitoring and insulin delivery systems. Therefore, stem-cell-based strategies have gained attention due to their potential to either replace lost β cells, modify immune responses, or accomplish both.

Recent developments utilizing mesenchymal stromal cells, hematopoietic stem cells, and β cells produced from pluripotent stem cells have demonstrated encouraging first results. Nevertheless, the majority of achievements to date have been from single-case or small patient cohorts. To direct future research and the translation process, a critical examination of unsolved problems and understudied regions is required. The section below discusses some

of the key knowledge gaps that would need to be covered for the realization of full therapeutic benefits of the use of stem-cell therapy for T1D.

Current State of Stem-Cell Therapy in T1D

The two main types of stem-cell ideas used to treat type 1 diabetes are immune-based (autologous hematopoietic stem cell transplantation) and cell replacement (mesenchymal or pluripotent stem-cell-derived insulin-producing cells). Long-term and widespread remission has not yet been attained, despite the fact that these strategies have somewhat raised C-peptide levels and decreased the need for insulin. The main gaps impeding future progress are listed in the following sections.



Key Unmet Research Gaps and Future Directions

1.Absence of Large-Scale, Long-Term Randomized Controlled Trials

Most clinical evidence to support stem-cell therapy in T1D comes from single-patient case reports, small cohort studies, or early phase (phase 1/2) trials. There is a lack of robust multicenter RCTs with long-term follow-up ≥5–10 years. Therefore, the durability of insulin independence, long-term safety, and efficacy at a population level of these therapies remain uncertain. Well-powered RCTs comparing stem-cell interventions with standard insulin therapy and among different stem-cell platforms must be a priority in future research.

2. Partial Characterization of Autoimmune Recurrence

While immune reset and immunomodulation strategies may achieve temporary suppression of autoimmune activity, relapse of autoimmunity remains a major challenge. The detailed immunological mechanisms promoting graft rejection or renewed β-cell destruction are poorly understood. Longitudinal immune profiling, including but not limited to T-cell

receptor clonality, B-cell memory responses, and cytokine dynamics, is desperately needed to identify predictors of sustained immune tolerance versus relapse.

3. Absence of Lasting Immune Protection in the absence of Systemic Immunosuppression

Most current clinical approaches rely on systemic immunosuppression or physical encapsulation to protect the transplanted cells. Long-term systemic immunosuppression is associated with unacceptable risks for young and otherwise healthy individuals with T1D, whereas encapsulation technologies suffer from fibrosis, limited nutrient diffusion, and declining graft performance. Immune-evasive or locally immune-modulating strategies that eliminate the need for systemic immunosuppression remain one of the biggest unmet needs in the development of

4. Suboptimal Vascularization and Oxygenation of Transplanted Cells

For the successful engraftment of β-cells, rapid vascularization and adequate oxygen supply are very important. Early hypoxia-induced apoptosis is one of the reasons for the compromise in therapeutic efficacy of many transplanted stem-cell–derived β cells. Optimal implantation sites and bioengineered scaffolds that allow vascular integration remain to be identified. Future studies should therefore concentrate on enhancing the oxygenation of grafts and their microenvironment support.

5. Long-Term Safety, Genetic Stability, and Tumorigenicity

Although the short-term safety profiles of pluripotent stem-cell–derived therapies appear acceptable, long-term risks including tumorigenicity and genomic instability remain poorly characterized. The processes of reprogramming, extended in vitro expansion, and gene editing carry potential to introduce genetic or epigenetic abnormalities. Extended post-transplant surveillance and standardized genomic safety assessments are needed prewidespread clinical adoption.

6. Lack of Standardization in β-Cell Differentiation and Functional Assessment

Substantial heterogeneity in β-cell differentiation protocols exists between laboratories and clinical studies; there is no consensus on what constitutes a functionally mature human β cell. As a result, there is variable glucose responsiveness and insulin secretory capacity among diverse studies. Standardized benchmarks of differentiated cells are required and should be

aligned with functional validation criteria that need to be defined to enable reproducibility and regulatory approval.

7. Evidence is Limited in Long-Standing and Pediatric Populations with T1D

Most clinical trials preferentially enroll newly diagnosed patients with residual endogenous insulin production. Consequently, the efficacy of stem-cell therapies in long-standing T1D and in the pediatric population remains largely unknown. Such underrepresentation makes it imperative that future clinical trials be expanded to include these populations to accurately establish the broader applicability of the stem-cell–based interventions.

8. Inadequate Assessment of Therapeutic Combination Strategies

It is unlikely that replacement with stem cells per se will be sufficient to achieve durable disease modification. However, combination strategies, such as the use of stem cells in combination with immune tolerance-inducing biologics, targeted immunotherapies, or gene-editing approaches, have been subjected to remarkably little systematic evaluation. Rationally designed combination therapies represent a promising but underexplored avenue of future investigation.

9. Manufacturing, Scalability, and Cost-Effectiveness Issues

High translation costs, complex GMP requirements, and limited scalability restrain the translation of stem-cell therapies into routine clinical practice. Autologous approaches, while offering broad immunological advantages, are often extremely resource-intensive. Comprehensive cost-effectiveness analyses and scalable manufacturing solutions need to be developed that will assure equitable global access.

10. Ethical, Regulatory, and Policy Considerations

Various regions have immensely differed ethical and regulatory pathways to stem-cell therapies, serving as a barrier to international collaboration and clinical translation. Many of the clear guidelines address pediatric use, gene-edited cells, long-term follow-up obligations, and equitable access. Regulatory standards will need harmonization in order for clinical implementation to occur responsibly.

CONCLUSION

Cell therapies utilizing stem cells are a revolutionary, but as yet experimental, strategy in the management of Type 1 Diabetic patients. Although initial successes in early clinical trials

offer concrete proof of the concept of β-cell replacement and immune modulation, many scientific, clinical, and translational issues remain unresolved, and these will become critical in optimizing the advancement of these therapies from the bench into the clinical practice. Only through the coordinated efforts of both the scientific and clinical communities will it be possible to assess and affirm whether stem cell therapy will finally bring a safe and accessible cure to Type 1 Diabetic patients.

Preclinical studies and phase I clinical trials yield promising results, yet the road to clinical translation is arduous owing to challenges including the risk of tumorigenicity, variable therapeutic efficacy, immune rejection, and changing regulatory landscapes. These challenges will require innovations in cell engineering, biomaterial science, and quality control protocols. Emerging technologies like CRISPR-based gene editing, 3D-bioprinted tissue constructs, and AI-optimized combinatorial regimens are poised to overcome current challenges and usher in standardized, scalable therapeutic platforms

REFERENCE

1. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404:2077–2093. doi: 10.1016/S0140-6736(24)02317-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Hirsch IB, Pihoker C, Roberts A, Zenno A, Le P, Lawrence JM, Casagrande SS, Herman WH, Wexler DJ, Cefalu WT. Medication Use and Self-Care Practices in Persons With Diabetes. In: Diabetes in America [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2023–. [PubMed] [Google Scholar]
3. Zahid M, Dowlatshahi S, Kansara AH, Sadhu AR. The Evolution of Diabetes Technology - Options Toward Personalized Care. Endocr Pract. 2023;29:653–662. doi: 10.1016/j.eprac.2023.04.007. [DOI] [PubMed] [Google Scholar]
4. Karwasra R, Sharma S, Sharma I, Shahid N, Umar T. Diabetology and Nanotechnology: A Compelling Combination. Recent Pat Nanotechnol. 2025;19:4–16. doi: 10.2174/0118722105253055231016155618. [DOI] [PubMed] [Google Scholar]
5. Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell. 2020;27:523–531. doi: 10.1016/j.stem.2020.09.014. [DOI] [PubMed] [Google Scholar]
6. Li H, Zhu H, Ge T, Wang Z, Zhang C. Mesenchymal Stem Cell-Based Therapy for Diabetes Mellitus: Enhancement Strategies and Future Perspectives. Stem Cell Rev Rep. 2021;17:1552–1569. doi: 10.1007/s12015-021-10139-5. [DOI] [PubMed] [Google Scholar]

7. Maestas MM, Bui MH, Millman JR. Recent progress in modeling and treating diabetes using stem cell-derived islets. Stem Cells Transl Med. 2024;13:949–958. doi: 10.1093/stcltm/szae059. [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–1300. doi: 10.1038/nature08933. [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346. doi: 10.1016/S0140-6736(05)61032-X. [DOI] [PubMed] [Google Scholar]
10. Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M. Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. Cell Stem Cell. 2018;22:810–823. doi: 10.1016/j.stem.2018.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Millman JR, Xie C, Van Dervort A, Gürtler M, Pagliuca FW, Melton DA. Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nat Commun. 2016;7:11463. doi: 10.1038/ncomms11463. [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Hogrebe NJ, Ishahak M, Millman JR. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell. 2023;30:530–548. doi: 10.1016/j.stem.2023.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Boumaza I, Srinivasan S, Witt WT, Feghali-Bostwick C, Dai Y, Garcia-Ocana A, Feili-Hariri M. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun. 2009;32:33–42. doi: 10.1016/j.jaut.2008.10.004. [DOI] [PubMed] [Google Scholar]
14. Dong Z, Fu Y, Cai Z, Dai H, He Y. Recent advances in adipose-derived mesenchymal stem cell-derived exosomes for regulating macrophage polarization. Front Immunol. 2025;16:1525466. doi: 10.3389/fimmu.2025.1525466. [DOI] [PMC free article] [PubMed] [Google Scholar]
15. Oliveira AG, Araújo TG, Carvalho BM, Rocha GZ, Santos A, Saad MJA. The Role of Hepatocyte Growth Factor (HGF) in Insulin Resistance and Diabetes. Front Endocrinol (Lausanne) 2018;9:503. doi: 10.3389/fendo.2018.00503. [DOI] [PMC free article] [PubMed] [Google Scholar]